SCHEMBL6628700

SCHEMBL6628700

C=CCC(C[C@H](NC(=O)[C@@H]1CCCN2C(=O)CC[C@H](NC(=O)NCCc3cccs3)C(=O)N12)C(=O)CSc1nnnn1-c1ccccc1)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
CASP1 P29466 7/20 0.38
IL1B P01584 2/20 0.36
ALDH1A1 P00352 3/20 0.35
TSHR P16473 2/20 0.35
POLB P06746 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 2/20 0.34
HSD17B10 Q99714 1/20 0.34
MME P08473 1/20 0.34
ACE P12821 1/20 0.34
LCK P06239 1/20 0.34
ADAM17 P78536 3/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6627270 0.89 CYP1A2 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19CASP1
SCHEMBL6627279 0.89 CYP1A2 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19CASP1
SCHEMBL6627276 0.89 CYP1A2 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19CASP1
SCHEMBL6630022 0.87 CYP1A2 (0.44) CYP1A2CYP3A4CYP2D6CYP2C19CASP1
SCHEMBL6626939 0.87 CYP1A2 (0.44) CYP1A2CYP3A4CYP2D6CYP2C19CASP1
SCHEMBL6628010 0.84 CASP1 (0.39) CASP1IL1BALDH1A1HTTMME
SCHEMBL6631747 0.84 CYP1A2 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19CASP1
SCHEMBL6630595 0.81 CASP1 (0.41) CYP1A2CYP3A4CYP2D6CYP2C19CASP1
SCHEMBL6627961 0.81 CASP1 (0.39) CASP1IL1BMMEACELCK
SCHEMBL645645 0.76 CASP1 (0.50) CASP1IL1BALDH1A1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1246824-B1 CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AVENTIS PHARMA SA (FR) 2004-06-09 EP claimed
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof AVENTIS PHARMA S.A. (FR) 2003-05-29 US claimed
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof AVENTIS PHARMA S.A. (FR) 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof HRH4, HRH3, HRH2 CYP1A2 212/4885CYP3A4 142/4885CYP2D6 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.